Women with borderline personality disorder may be at greater risk of perimenstrual worsening of emotional symptoms, with secondary worsening in the midluteal and follicular phases, as reported in a recent study.
Psychological interventions appear to provide minimal benefits in improving anxiety in patients with cancer, according to a recent meta-analysis. Lack of substantial distress at baseline may contribute to this effect.
Use of opioid pain medication among adults with comorbid symptoms of insomnia and chronic pain appears to prolong time spent being awake in bed, reports a study, adding that such effect cannot be attributed to changes in pain, use of sleep medication or total sleep time.
Early and longer treatment time with long-acting injectable antipsychotics may result in better psycho‐socio‐occupational functioning in patients with schizophrenia or schizoaffective disorder, particularly those with lower number of prescribed oral drugs and fewer hospitalizations, according to a study.
Guided online Cognitive Behavioral Therapy for Insomnia (CBT-I) may be used in the management of both insomnia and depressive symptoms, with effect sizes being large and comparable to that of depression therapy, according to a study.
Use of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) is suitable for a quick assessment of patient cognition during multiple sclerosis (MS) relapse, a recent study has shown.
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
A treatment regimen combining daratumumab plus bortezomib, melphalan and prednisone markedly extends progression-free survival in patients with multiple myeloma, inducing deep responses and demonstrating acceptable tolerability regardless of baseline renal function, according to the results of the phase III ALCYONE study.
Segmentectomy and lobectomy confer similar overall survival (OS) and lung cancer-specific survival (LCSS) among patients with primary nonsmall cell lung cancer (NSCLC) of ≤20 mm without lymph node or distant metastasis, a recent study has shown.